Skip to main content

Table 2 Population demographic and clinical characteristics for female sub-cohorts

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

   LUTS (including OAB) N = 29,094 SUI N = 1688
Age at index date n 29,094 1688
  Mean (SD) 62.92 (16.77) 54.24 (16.29)
  18–24 604 (2.1%) 32 (1.9%)
  25–34 1121 (3.9%) 159 (9.4%)
  35–44 2536 (8.7%) 315 (18.7%)
  45–54 4835 (16.6%) 399 (23.6%)
  55–64 5264 (18.1%) 315 (18.7%)
  65–74 6446 (22.2%) 248 (14.7%)
  ≥ 75 8288 (28.5%) 220 (13.0%)
Index of multiple deprivation at index prescription (GP surgery level) n 11,999 665
  1 = least deprived 1534 (12.8%) 86 (12.9%)
  2 2418 (20.2%) 148 (22.3%)
  3 2292 (19.1%) 137 (20.6%)
  4 2285 (19.0%) 105 (15.8%)
  5 = most deprived 3470 (28.9%) 189 (28.4%)
New comorbidities n 29,094 1688
Count of newly diagnosed chronic diseases from the QOF within the 12-month pre-index period Mean (SD) 0.20 (0.48) 0.23 (0.53)
  0 24,327 (83.6%) 1374 (81.4%)
  1 3950 (13.6%) 248 (14.7%)
  2 712 (2.4%) 56 (3.3%)
  3+ 105 (0.4%) 10 (0.6%)
Polypharmacy n 29,094 1688
Number of distinct BNF headers within the 12-month pre-index period Mean (SD) 10.77 (7.49) 11.55 (7.42)
  0 681 (2.3%) 29 (1.7%)
  [1; 3] 3766 (12.9%) 165 (9.8%)
  [4; 7] 6944 (23.9%) 384 (22.7%)
  [8; 19] 14,178 (48.7%) 873 (51.7%)
  20+ 3525 (12.1%) 237 (14.0%)
Antimuscarinic treatment experience within the 12-month pre-index period n 29,094 1688
  Yes 2681 (9.2%) 56 (3.3%)
  No 26,413 (90.8%) 1632 (96.7%)
  1. Female LUTS (including OAB) sub-cohort patients were those receiving an OAB drug (antimuscarinic and/or mirabegron) with or without a SUI drug (duloxetine). Female SUI sub-cohort patients were those receiving duloxetine without an OAB drug. Percentages may not total exactly 100 due to rounding
  2. BNF: British National Formulary; GP: general practitioner; LUTS: lower urinary tract symptoms; OAB: overactive bladder; QOF: Quality and Outcomes Framework; SD: standard deviation; SUI: stress urinary incontinence